Aurinia appoints Dr. Karen Smith and Jeffrey A. Bailey to Board; Dr. Daniel G. Billen named Chair

Aurinia Pharmaceuticals Inc.

Dr. Karen Smith and Jeffrey A. Bailey joined Aurinia's Board effective August 18, 2023, bringing decades of biopharma leadership experience.
Dr. Daniel G. Billen, board member since 2019, appointed Chair of the Board of Directors.
Both new directors have experience with successful sales, mergers, and partnerships, relevant to the ongoing strategic review process.
Dr. Smith has served on boards of several acquired companies (Forward Pharma, Sucampo, Acceleron, Antares Pharma).
Mr. Bailey has held CEO and Chairman roles, including Chairman of Tekla Capital Management since 2020.

item 5.02 item 9.01

Executive movements

Machine-extracted from this filing. Every card cites the SEC source. See all recent executive movements.

Appointed

Jeffrey A. Bailey

Director

AUPH · Aurinia Pharmaceuticals Inc.

Effective: 2023-08-18
Filed: August 21, 2023, 7:59 PM ET

On August 21, 2023, Aurinia Pharmaceuticals Inc. (the Company) issued a press release announcing the appointments of Dr. Karen Smith and Jeffrey A. Bailey to the Board of Directors of the Company (the Board) effective August 18, 2023.

Appointed

Dr. Karen Smith

Director

AUPH · Aurinia Pharmaceuticals Inc.

Effective: 2023-08-18
Filed: August 21, 2023, 7:59 PM ET

On August 21, 2023, Aurinia Pharmaceuticals Inc. (the Company) issued a press release announcing the appointments of Dr. Karen Smith and Jeffrey A. Bailey to the Board of Directors of the Company (the Board) effective August 18, 2023.

Key facts

Extracted from this filing and checked against the source text.

Executive change SEC 8-K Item 5.02 confidence 0.95

Jeffrey A. Bailey was appointed as Director at Aurinia Pharmaceuticals Inc..

Action: appointed
Role: Director

Exact text from the filing

On August 21, 2023, Aurinia Pharmaceuticals Inc. (the Company) issued a press release announcing the appointments of Dr. Karen Smith and Jeffrey A. Bailey to the Board of Directors of the Company (the Board) effective August 18, 2023.

View on SEC.gov

Executive change SEC 8-K Item 5.02 confidence 0.95

Dr. Karen Smith was appointed as Director at Aurinia Pharmaceuticals Inc..

Action: appointed
Role: Director

Exact text from the filing

On August 21, 2023, Aurinia Pharmaceuticals Inc. (the Company) issued a press release announcing the appointments of Dr. Karen Smith and Jeffrey A. Bailey to the Board of Directors of the Company (the Board) effective August 18, 2023.

View on SEC.gov

Aurinia Pharmaceuticals Inc. filing history →

Source: SEC EDGAR

accession 0001600620-23-000030

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.